Detail akcie Cyclacel Pharma Rg online

Business Summary: Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Cyclacel Pharmaceuticals Inc revenues decreased from $29K to $0K. Net loss decreased 97% to $81K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development - other decrease of 73% to $748K (expense). Dividend per share totaled to $2.25.